Explore
Clear Cell Renal Cell Carcinoma 2021–2022
0 Ungluers have
Faved this Work
Login to Fave
Clear cell renal cell carcinoma is currently one of the most interesting areas of study in oncology. Despite the advances made in this field, this tumor continues to be a health problem of major concern in Western societies, seriously affecting public health services. Several characteristics of this tumor make it an exciting meeting point for translational collaboration between clinicians and basic researchers. Clear cell renal cell carcinoma is a paradigmatic example of inter- and intra-tumor heterogeneity from morphological, immunohistochemical, and molecular viewpoints. This tumor is also a good example to investigate the complexity of tumor/tumor and tumor/environment relationships from an ecological perspective. A deeper identification of the varied internal tumor self-organization through the specialization of cell clones and subclones as local invaders and metastasizers, on one hand, and the interactions of specific subsets of tumor cells with the local host microenvironment, on the other, will significantly enrich our knowledge of this neoplasm. Clear cell renal cell carcinoma is also a paradigmatic test bench for antiangiogenic and immune checkpoint blockage therapies. The refinement of these therapeutic tools administered alone or in combination is a hot issue in oncology, and several international trials are underway.
This book is included in DOAB.
Why read this book? Have your say.
You must be logged in to comment.
Rights Information
Are you the author or publisher of this work? If so, you can claim it as yours by registering as an Unglue.it rights holder.Downloads
This work has been downloaded 32 times via unglue.it ebook links.
- 32 - pdf (CC BY) at Unglue.it.
Keywords
- adjuvant therapy
- Angiogenesis
- architectural patterns
- biomarker
- biomarkers
- cancer immunotherapy
- circulating miRNA
- clear cell kidney cancer
- clear cell renal cell carcinoma
- clear-cell renal cell carcinoma
- Clinical & internal medicine
- combinations
- cutaneous
- cystic tumor
- ddPCR
- Diagnosis
- disease progression
- DNA Methylation
- endothelial cells
- epigenetics
- first-line treatment
- Gene expression
- histomorphological features
- hypoxia
- imaging
- immune checkpoint inhibitor
- immune checkpoint inhibitors
- immune landscape
- immune related adverse events (irAEs)
- immunohistochemistry
- Immunotherapy
- inter-metastatic heterogeneity
- inter-tumoral heterogeneity
- intra-tumoral heterogeneity
- intratumor heterogeneity
- Kidney
- Machine learning
- magnetic resonance
- malignancy
- medicine
- metastatic clear cell renal cell carcinoma
- miRNA
- molecular features
- multisite tumor sampling
- n/a
- Nivolumab
- oleic acid
- pathway analysis
- PBRM1
- PD-1
- PD-L1
- PD1
- Plasma
- prediction model
- prognosis
- prognostic factor
- prognostic factors
- radiogenomics
- radiomics
- renal cancer
- renal cell cancer
- renal cell carcinoma
- Resistance
- responsiveness
- RNA sequencing
- SCD-1
- single-cell RNA sequencing
- sunitinib
- Surgery
- T-cells
- thyroid
- tissue slice culture
- transcriptome
- translational
- treatment resistance
- Tumor microenvironment
- Tyrosine kinase inhibitors
Links
DOI: 10.3390/books978-3-0365-5518-8Editions